Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 180

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 180
---
-phase patent applications. At the end of the period of 30 months from
the first priority date of the provisional patent application, separate national phase patent applications can be pursued in any of the
PCT member states either by direct national filing, or in some cases, by filing through a regional patent organization, such as the European
Patent Office. The PCT system delays expenses, allows a limited evaluation of the chances of success for national/regional patent applications,
and enables substantial savings where applications are abandoned within the first thirty months of filing.

For all patent applications,
we determine claiming strategy on a case-by-case basis. Advice of counsel and our business model and needs are always considered. We
continuously reassess the number and type of patent applications, as well as the scope of our patent claims to pursue coverage and value
for our processes and compositions, given existing patent office rules and regulations. Further, claims may be modified during patent
prosecution to meet our intellectual property and business needs.

We have sought patent protection
in the United States and various international jurisdictions related to the CER-1236 T cell technology platform and its constructs, as
well as their use as individual cellular compositions and product candidates targeting specific diseases. We also intend to seek patent
protection related to the processes and materials used in CER-1236 T cell expression as well as its use in combination therapies. As
of December 2, 2024, our patent portfolio comprises nine different patent families filed in various jurisdictions worldwide. These patent
families include two issued patents in the United States, one of which relates to CER-1236; 34 pending U.S. applications; twelve issued
patents in France, Germany, Italy, Spain, United Kingdom, China, Japan, Hong Kong, and Mexico; and 29 pending applications in Canada,
China, Europe, Hong Kong, Japan, and Korea. These patents and applications, if and when issued, are projected to expire from 2037 to
2042, absent any available patent term adjustments or extensions. We intend to pursue, when possible, further composition, method of
use, dosing, formulation, and other patent protection directed to our current and new product candidates. We may also pursue patent protection
with respect to manufacturing and drug development processes and technology.

<div align='center'>106</div>

The following issued patents
are directed at a composition of matter and provide coverage for our CER-1236 T cell candidate:

U.S. Patent